Lenvima (lenvatinib capsules) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has advanced disease
• Patient meets ONE of the following (i or ii):
• i. Lenvima is being used in combination with Keytruda (pembrolizumab intravenous infusion)
• ii. Lenvima is being used in combination with everolimus tablets/Afinitor Disperz (everolimus tablets for oral suspension) AND patient meets one of the following (a or b):
• a) Patient has clear cell histology and has tried one antiangiogenic therapy
• b) Patient has non-clear cell histology

Approval duration

1 year